bpc-157 human clinical trials 2026 trial humans kpv bpc 157 tb500 dihexa human status SCOPE 2026, Simplified Patient Recruitment Management, AI Powered Clinical Trial Finders Research Breakdown on BPC-157 FDA advisory committee votes to

Protocol approach: frozen shoulder (adhesive capsulitis) Goal: Reduce capsular fibrosis, restore range of motion, manage pain Peptide approach: BPC-157: 300 to 500 mcg daily for anti-inflammatory and tissue healing properties TB-500: 500 to 750 mcg twice weekly for systemic anti-inflammatory and tissue remodeling Note on relaxin-2: While the most specifically targeted peptide for this condition, it remains largely in the research phase and is not widely available through standard channels Duration: Twelve to sixteen weeks (frozen shoulder has a prolonged natural course) Critical addition: Aggressive physical therapy within pain tolerance

Expect French classics with an ancestral West Indian twist such as foie gras with rum from Marie Galante and scallops and Colombo spices

Gentle scalp scrubs or chemical exfoliants remove accumulated debris from follicle openings, creating clearer pathways for peptide penetration

This not only enhances injury recovery but may improve cardiovascular health through circulatory increase and blood pressure stabilization [11, 32, 33]